Home » Topics » Disease categories and therapies » Hematologic

Hematologic
RSS

rNAPc2 completes phase Ia testing with positive results

Sep. 25, 1997

Lilly presents structurally novel thrombin inhibitors

Sep. 24, 1997

First approvals for Lovenox/Clexane in unstable angina/MI

Sep. 22, 1997

TP-9201 as adjunct to thrombolysis in stroke

Sep. 22, 1997

Lilly describes lead for orally active thrombin inhibitors

Sep. 19, 1997

Bisulfated peptide may be clinically useful in venous thrombotic disorders

Sep. 17, 1997

Long-term effects of abciximab in PTCA

Sep. 16, 1997

Molecumetics and Teijin begin oral thrombin inhibitor collaboration

Sep. 15, 1997

Pharmacological characterization of BIBU-52

Sep. 15, 1997

LG Chemical licenses thrombin inhibitor to Warner-Lambert

Sep. 15, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 24, 2026.
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 24, 2026